Organoids and Organ Chip Services for Brain Tumors

The use of brain tumor organoids and organ chips has been instrumental in identifying novel therapeutic targets and evaluating the efficacy of anti-cancer drugs. At Alfa Cytology, we specialize in providing cutting-edge organoid and organ chip services tailored for brain tumor research.

Introduction to Brain Tumor Organoid and Organ Chip Models

The advancement of organoid and organ chip technologies has revolutionized the field of cancer research, particularly in the study of brain tumors. Organoids, which are 3D structures derived from stem cells, mimic the architecture and functionality of actual organs. These models provide a more physiologically relevant environment compared to traditional 2D cell cultures, enabling researchers to gain profound insights into tumor biology, drug responses, and therapeutic efficacy.

Fig.1 Construction of organoid models of brain tumors. (Park, J.H., et al., 2024)

Brain tumors, including gliomas and meningiomas, present unique challenges due to their complex microenvironment, cellular heterogeneity, and the blood-brain barrier (BBB). Organoids derived from patient-specific tumor cells can replicate these characteristics, allowing for the study of tumor progression and response to treatment. Additionally, organ chips—microfluidic devices that integrate organoids—offer a dynamic platform to simulate the interactions between brain tumors and their microenvironment, providing a more accurate representation of in vivo conditions.

Our Services

At Alfa Cytology, we are committed to advancing brain tumor research through our specialized organoid and organ chip services. Our offerings are designed to support researchers in their quest to understand brain tumors and develop innovative therapies. Our specialized services in brain tumor organoid and organ chip modeling provide researchers with advanced platforms to investigate tumor biology, drug responses, and therapeutic strategies.

Comprehensive Organoid Generation Services

We utilize advanced protocols to generate brain tumor organoids from patient-derived samples. Our team employs both unguided and regionalized differentiation methods, ensuring the production of organoids that closely resemble the original tumor architecture and cellular composition.

Glioblastoma Organoid Generation
Meningioma Organoid Generation
Astrocytoma Organoid Generation

Advanced Brain Tumors Organ Chip Services

Our organ chip technology integrates brain tumor organoids into microfluidic systems for real-time analysis of tumor behavior under controlled physiological conditions, including nutrient flow and oxygenation, to study the impact of the microenvironment on tumor growth and therapy responses.

Micro-physiology System Chips Development
Drug Discovery/Screening Chips Development
Disease Modeling Chips Development
Pharmacological Assay Chips Development

Case Study - Patient-Derived Glioblastoma Organoid (GBO) Model

Model Introduction

The patient-derived glioblastoma organoid (GBO) model provides a physiologically relevant preclinical platform for studying glioblastoma biology and evaluating therapeutic strategies. Derived from patient tumor tissue, this model preserves the cellular heterogeneity, genetic profile, and histopathological features of the original tumor, including glioblastoma stem cell (GSC) populations. Unlike traditional 2D cell cultures or xenograft models, GBOs recapitulate the three-dimensional architecture, cellular diversity, and spatial organization of human GBM, enabling more accurate assessment of tumor biology and drug responses.

Model Information

Model: Patient-Derived Glioblastoma Organoid (GBO) Model
Cell Line: Patient-derived Glioblastoma Stem Cells (GSCs)

Cancer Type: Glioblastoma
Culture System: 3D Matrigel-Based Organoid Culture

Model Construction

The model is established through a sequential two-phase protocol.

Glioblastoma Stem Cell Isolation Phase: Fresh patient-derived GBM tissue is processed to isolate glioblastoma stem cells (GSCs) using serum-free stem cell culture conditions. GSCs are confirmed by immunofluorescence staining for stemness markers.
Organoid Formation and Maintenance Phase: GSCs are embedded in an extracellular matrix scaffold and cultured in organoid medium. Organoids form within one week, exhibiting spherical morphology, and can be serially passaged, cryopreserved, and recovered for long-term maintenance.

Fig. 2 Workflow of IOMM-Lee xenograft model establishment. (Source: Alfa Cytology)

Model Data

High Histopathological and Molecular Fidelity: GBOs faithfully retain the histological morphology of the original patient tumor, as confirmed by HE staining. Immunofluorescence confirms expression of stemness markers (SOX2, CD133, Nestin) and recapitulates the proliferation (Ki-67) and apoptosis (caspase 3) distribution patterns observed in human GBM tissue.
In Vivo Tumorigenicity: Orthotopic implantation of GBO-derived cells into nude mice results in robust tumor formation within 30 days, with superior tumorigenic capacity compared to conventional GBM cell lines.
Long-Term Stability and Scalability: GBOs can be serially passaged, cryopreserved, and recovered without loss of key characteristics.

Fig. 3 Results of GBM organoid in situ tumorigenesis experiment in nude mice. Data are presented as mean ± standard error (SEM). (Source: Alfa Cytology)

Contact Us

Alfa Cytology can combine organoid culture and imaging services with live cell imaging, microfluidic microarrays, and bio-3D printing, which can provide new avenues for disease diagnosis, treatment option selection, and drug screening of brain tumors. Please contact our staff to learn how we can provide these services for you.

Reference

Park J. H., et al. (2024) Vaccine-based immunotherapy and related preclinical models for glioma[J]. Trends in Molecular Medicine. 30, 10, 965 - 981.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.